GMAB
Price
$20.80
Change
-$0.42 (-1.98%)
Updated
Jan 17 closing price
Capitalization
13.38B
25 days until earnings call
PGEN
Price
$1.11
Change
-$0.00 (-0.00%)
Updated
Jan 17 closing price
Capitalization
325.08M
39 days until earnings call
Ad is loading...

GMAB vs PGEN

Header iconGMAB vs PGEN Comparison
Open Charts GMAB vs PGENBanner chart's image
Genmab A/S ADS
Price$20.80
Change-$0.42 (-1.98%)
Volume$1.12M
Capitalization13.38B
Precigen
Price$1.11
Change-$0.00 (-0.00%)
Volume$1.15M
Capitalization325.08M
GMAB vs PGEN Comparison Chart
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. PGEN commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and PGEN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (GMAB: $20.80 vs. PGEN: $1.11)
Brand notoriety: GMAB and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 92% vs. PGEN: 72%
Market capitalization -- GMAB: $13.38B vs. PGEN: $325.08M
GMAB [@Biotechnology] is valued at $13.38B. PGEN’s [@Biotechnology] market capitalization is $325.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, PGEN is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 5 bullish TA indicator(s).

  • GMAB’s TA Score: 4 bullish, 3 bearish.
  • PGEN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than PGEN.

Price Growth

GMAB (@Biotechnology) experienced а -6.09% price change this week, while PGEN (@Biotechnology) price change was -5.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

GMAB is expected to report earnings on May 08, 2025.

PGEN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($13.4B) has a higher market cap than PGEN($325M). GMAB YTD gains are higher at: -0.335 vs. PGEN (-0.893). GMAB has higher annual earnings (EBITDA): 6.97B vs. PGEN (-136.11M). GMAB has more cash in the bank: 17.3B vs. PGEN (28.6M). PGEN has less debt than GMAB: PGEN (5.75M) vs GMAB (987M). GMAB has higher revenues than PGEN: GMAB (19.8B) vs PGEN (3.96M).
GMABPGENGMAB / PGEN
Capitalization13.4B325M4,123%
EBITDA6.97B-136.11M-5,120%
Gain YTD-0.335-0.89338%
P/E Ratio20.82N/A-
Revenue19.8B3.96M499,621%
Total Cash17.3B28.6M60,490%
Total Debt987M5.75M17,168%
FUNDAMENTALS RATINGS
GMAB vs PGEN: Fundamental Ratings
GMAB
PGEN
OUTLOOK RATING
1..100
1723
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5699
PRICE GROWTH RATING
1..100
6139
P/E GROWTH RATING
1..100
85100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (62) in the null industry is in the same range as GMAB (67). This means that PGEN’s stock grew similarly to GMAB’s over the last 12 months.

PGEN's Profit vs Risk Rating (100) in the null industry is in the same range as GMAB (100). This means that PGEN’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (56) in the null industry is somewhat better than the same rating for PGEN (99). This means that GMAB’s stock grew somewhat faster than PGEN’s over the last 12 months.

PGEN's Price Growth Rating (39) in the null industry is in the same range as GMAB (61). This means that PGEN’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's P/E Growth Rating (85) in the null industry is in the same range as PGEN (100). This means that GMAB’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABPGEN
RSI
ODDS (%)
Bearish Trend 11 days ago
54%
Bearish Trend 11 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
69%
Bearish Trend 11 days ago
90%
Momentum
ODDS (%)
Bullish Trend 11 days ago
60%
Bullish Trend 11 days ago
85%
MACD
ODDS (%)
Bullish Trend 11 days ago
59%
Bullish Trend 11 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
64%
Bullish Trend 11 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
65%
Bullish Trend 11 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
64%
Bullish Trend 12 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 23 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
59%
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Ad is loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
ACM.X1.5294680.064599
+4.41%
AC Milan Fan Token cryptocurrency
ORDI.X27.3134461.018003
+3.87%
ORDI cryptocurrency
POWR.X0.2883710.009142
+3.27%
Powerledger cryptocurrency
MBL.X0.0036350.000089
+2.51%
MovieBloc cryptocurrency
XLM.X0.4884370.006129
+1.27%
Stellar cryptocurrency

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.98%
GNMSF - GMAB
58%
Loosely correlated
-1.04%
AXON - GMAB
47%
Loosely correlated
+1.37%
CVAC - GMAB
39%
Loosely correlated
-1.91%
PGEN - GMAB
36%
Loosely correlated
N/A
VCYT - GMAB
35%
Loosely correlated
-1.27%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with RCKT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
N/A
RCKT - PGEN
47%
Loosely correlated
+0.98%
IDYA - PGEN
44%
Loosely correlated
-2.38%
ALEC - PGEN
44%
Loosely correlated
+1.79%
AVIR - PGEN
43%
Loosely correlated
+1.20%
NKTX - PGEN
42%
Loosely correlated
-0.80%
More